

**REMARKS**

Claims 1-6 and 28-41 were pending in the present application. Claims 1, 4, 5, 35, and 36 have been amended herein. No new matter has been added. Upon entry of the present amendments, claims 1-6 and 28-41 will remain pending.

**I. The Claimed Invention is Enabled**

Claims 1-6 and 28-31 are rejected under 35 U.S.C. §112, first paragraph, for allegedly failing to comply with the enablement requirement. Although Applicants disagree, solely to advance prosecution of the present application, Applicants have amended claim 1 to recite “for inducing an immune response,” as suggested by the Examiner. Applicants thank the Examiner for indicating that introduction of such language into the claim would obviate the enablement rejection. In light of the foregoing discussion, Applicants respectfully assert that the claimed invention is enabled, and request that the claim rejection be withdrawn.

**II. The Claimed Invention is Supported by Ample Written Description**

Claims 4 and 35 are rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the written description requirement. In particular, the Office alleges that “Applicant is not in possession of the recited genus of ‘co-stimulatory molecules’” (see, Final Rejection at page 4). Although Applicants disagree, solely to advance prosecution of the present application, Applicants have amended claims 4 and 35 to no longer recite “co-stimulatory molecules.” In light of the foregoing discussion, Applicants respectfully assert that the claimed invention is supported by ample written description, and request that the claim rejection be withdrawn.

**III. Conclusion**

In view of the foregoing, Applicants respectfully submit that the claims are in condition for allowance. An early notice of the same is earnestly solicited. The Office is invited to contact Applicants’ undersigned representative at 610.640.7859 if there are any questions regarding Applicants’ claimed invention.

**DOCKET NO.: 133088.00901 (P35703US)**

**PATENT**

The Commissioner is hereby authorized to debit any underpayment of fee due or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

/Paul K. Legaard, Reg.# 38534/  
Paul K. Legaard, Ph.D.

**Date: 23 September 2008**

Pepper Hamilton LLP  
400 Berwyn Park  
899 Cassatt Road  
Berwyn, PA 19312-1183

Telephone: 610.640.7859  
Facsimile: 267.430.7647